BioSpace News Archive

Genetown

Entrinsic Health Solutions Announce Journal of Parenteral and Enteral Nutrition Publication of Clinical Data Comparing Efficacy of Rehydration Therapies

Enterade® replaces electrolytes and preserves fluid retention better compared to sports drinks

March 14, 2018
·
5 min read
Drug Development

Alnylam to Report New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis

The APOLLO Phase 3 study of patisiran is an investigational therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis.

March 14, 2018
·
12 min read
FDA

Jupiter Orphan Therapeutics Announces Submission of Investigational New Drug Application (IND) For Treatment Of Mucopolysaccharidosis Type-I

Jupiter Orphan Therapeutics, Inc. (“JOT”), Jupiter, FL, today announced that it had submitted its IND to the FDA on March 12, 2018 for Mucopolysaccharidosis Type-I (MPSI).

March 14, 2018
·
3 min read
Business

Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

“We’ve made significant progress in 2017, achieving the clinical and corporate objectives we set forth as a new team,” said Amit D. Munshi, president and CEO.

March 14, 2018
·
17 min read
Nucleix Announces its Bladder EpiCheck™ Availability on the QIAGEN Rotor-Gene Q Platform

Significantly extending the commercial potential reach for Bladder EpiCheck

March 14, 2018
·
1 min read
Drug Development

TARIS® Initiates Dosing of TAR-200 (GemRIS™) in Muscle-Invasive Bladder Cancer Patients Unfit for Curative Intent Therapy

TARIS announced today that it has initiated dosing in a clinical trial of TAR-200 (GemRIS™) in patients with Muscle Invasive Bladder Cancer (MIBC) who are unfit for therapy with curative intent.

March 14, 2018
·
3 min read
FDA

FDA Accepts for Filing Supplemental Biologics License Application (sBLA) for Xeomin® (incobotulinumtoxinA) in Adult Patients with Sialorrhea

The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in Q4 2018, and if approved, has the potential to make Xeomin the first neurotoxin with this indication in the U.S.

March 14, 2018
·
9 min read
BioMidwest

ViewRay Finalizes Order for MR Image-Guided Radiation Therapy System at University Hospital Zurich

Oncologists at Leading Swiss Hospital Select MRIdian Linac as Preferred Technology In Competitive European Tender

March 14, 2018
·
4 min read
BioMidwest

Mardil Medical Announces First Human Implants of the VenTouch® Triad Targeted Ventricular Reshaping System

First technology to simultaneously treat the root causes of Type IIIb Functional Mitral Valve Regurgitation

March 14, 2018
·
3 min read
BioMidwest

Modern Healthcare Honors Fresenius Medical Care North America’s Saurabh Tripathi with Minority Executives to Watch in Healthcare Award

The profiles of all the winners were featured in the February 26, 2018 print issue of Modern Healthcare

March 14, 2018
·
3 min read